Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Cash & Equivalents (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Cash & Equivalents for 10 consecutive years, with $24.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 20.58% year-over-year to $24.0 million, compared with a TTM value of $24.0 million through Dec 2025, up 20.58%, and an annual FY2025 reading of $24.0 million, up 20.58% over the prior year.
  • Cash & Equivalents was $24.0 million for Q4 2025 at VYNE Therapeutics, up from $19.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $118.5 million in Q1 2021 and bottomed at $47000.0 in Q3 2024.
  • Average Cash & Equivalents over 5 years is $39.2 million, with a median of $30.6 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 105.75% in 2021, then plummeted 99.7% in 2024.
  • Year by year, Cash & Equivalents stood at $42.2 million in 2021, then dropped by 26.84% to $30.9 million in 2022, then decreased by 0.93% to $30.6 million in 2023, then plummeted by 34.92% to $19.9 million in 2024, then increased by 20.58% to $24.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for VYNE at $24.0 million in Q4 2025, $19.9 million in Q4 2024, and $47000.0 in Q3 2024.